Second acute leukemia and other malignancies following treatment for Hodgkin's disease

P. Valagussa, A. Santoro, F. Fossati-Bellani, A. Banfi, G. Bonadonna

Research output: Contribution to journalArticle

249 Citations (Scopus)

Abstract

The records of 1,329 patients with Hodgkin's disease admitted from 1965 to 1982 were analyzed to assess the relative frequency of second neoplasms. Within a median follow-up of 9.5 years, a total of 68 new cancers were documented. Nineteen cases of acute nonlymphocytic leukemia, 6 cases of non-Hodgkin's lymphomas, and 43 cases with different types of solid tumors were identified. The overall risk of non-Hodgkin's lymphoma was 1.3% ± 0.6% and of solid tumors was 8.3% ± 1.5% when basal cell carcinomas were included and 6.7% ± 1.4% when basal cell carcinomas were excluded. No cases of leukemia were documented in patients treated with radiation therapy only. The 12-year estimate of leukemia by treatment was as follows: chemotherapy only 1.4% ± 2.3%; radiation plus MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) 10.2% ± 5.2%; radiation plus ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine) 0; and radiation plus other drug regimens 4.8% ± 1.6%. The risk of leukemia was particularly high (15.5% ± 7.4%) in patients who received salvage MOPP after radiation failure. A positive association was also noted between increasing age and risk of second malignancies, especially leukemia. The incidence of second neoplasms can be markedly decreased by deleting from potentially curative therapy certain drugs such as alkylating agents, procarbazine, and nitrosourea derivatives.

Original languageEnglish
Pages (from-to)830-837
Number of pages8
JournalJournal of Clinical Oncology
Volume4
Issue number6
Publication statusPublished - 1986

Fingerprint

Procarbazine
Hodgkin Disease
Second Primary Neoplasms
Leukemia
Radiation
Mechlorethamine
Basal Cell Carcinoma
Vincristine
Prednisone
Non-Hodgkin's Lymphoma
Neoplasms
Drug Therapy
Dacarbazine
Vinblastine
Alkylating Agents
Bleomycin
Therapeutics
Acute Myeloid Leukemia
Doxorubicin
Radiotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Valagussa, P., Santoro, A., Fossati-Bellani, F., Banfi, A., & Bonadonna, G. (1986). Second acute leukemia and other malignancies following treatment for Hodgkin's disease. Journal of Clinical Oncology, 4(6), 830-837.

Second acute leukemia and other malignancies following treatment for Hodgkin's disease. / Valagussa, P.; Santoro, A.; Fossati-Bellani, F.; Banfi, A.; Bonadonna, G.

In: Journal of Clinical Oncology, Vol. 4, No. 6, 1986, p. 830-837.

Research output: Contribution to journalArticle

Valagussa, P, Santoro, A, Fossati-Bellani, F, Banfi, A & Bonadonna, G 1986, 'Second acute leukemia and other malignancies following treatment for Hodgkin's disease', Journal of Clinical Oncology, vol. 4, no. 6, pp. 830-837.
Valagussa, P. ; Santoro, A. ; Fossati-Bellani, F. ; Banfi, A. ; Bonadonna, G. / Second acute leukemia and other malignancies following treatment for Hodgkin's disease. In: Journal of Clinical Oncology. 1986 ; Vol. 4, No. 6. pp. 830-837.
@article{42f3bec58f674f92b2935a4f6ee60ad7,
title = "Second acute leukemia and other malignancies following treatment for Hodgkin's disease",
abstract = "The records of 1,329 patients with Hodgkin's disease admitted from 1965 to 1982 were analyzed to assess the relative frequency of second neoplasms. Within a median follow-up of 9.5 years, a total of 68 new cancers were documented. Nineteen cases of acute nonlymphocytic leukemia, 6 cases of non-Hodgkin's lymphomas, and 43 cases with different types of solid tumors were identified. The overall risk of non-Hodgkin's lymphoma was 1.3{\%} ± 0.6{\%} and of solid tumors was 8.3{\%} ± 1.5{\%} when basal cell carcinomas were included and 6.7{\%} ± 1.4{\%} when basal cell carcinomas were excluded. No cases of leukemia were documented in patients treated with radiation therapy only. The 12-year estimate of leukemia by treatment was as follows: chemotherapy only 1.4{\%} ± 2.3{\%}; radiation plus MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) 10.2{\%} ± 5.2{\%}; radiation plus ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine) 0; and radiation plus other drug regimens 4.8{\%} ± 1.6{\%}. The risk of leukemia was particularly high (15.5{\%} ± 7.4{\%}) in patients who received salvage MOPP after radiation failure. A positive association was also noted between increasing age and risk of second malignancies, especially leukemia. The incidence of second neoplasms can be markedly decreased by deleting from potentially curative therapy certain drugs such as alkylating agents, procarbazine, and nitrosourea derivatives.",
author = "P. Valagussa and A. Santoro and F. Fossati-Bellani and A. Banfi and G. Bonadonna",
year = "1986",
language = "English",
volume = "4",
pages = "830--837",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "6",

}

TY - JOUR

T1 - Second acute leukemia and other malignancies following treatment for Hodgkin's disease

AU - Valagussa, P.

AU - Santoro, A.

AU - Fossati-Bellani, F.

AU - Banfi, A.

AU - Bonadonna, G.

PY - 1986

Y1 - 1986

N2 - The records of 1,329 patients with Hodgkin's disease admitted from 1965 to 1982 were analyzed to assess the relative frequency of second neoplasms. Within a median follow-up of 9.5 years, a total of 68 new cancers were documented. Nineteen cases of acute nonlymphocytic leukemia, 6 cases of non-Hodgkin's lymphomas, and 43 cases with different types of solid tumors were identified. The overall risk of non-Hodgkin's lymphoma was 1.3% ± 0.6% and of solid tumors was 8.3% ± 1.5% when basal cell carcinomas were included and 6.7% ± 1.4% when basal cell carcinomas were excluded. No cases of leukemia were documented in patients treated with radiation therapy only. The 12-year estimate of leukemia by treatment was as follows: chemotherapy only 1.4% ± 2.3%; radiation plus MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) 10.2% ± 5.2%; radiation plus ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine) 0; and radiation plus other drug regimens 4.8% ± 1.6%. The risk of leukemia was particularly high (15.5% ± 7.4%) in patients who received salvage MOPP after radiation failure. A positive association was also noted between increasing age and risk of second malignancies, especially leukemia. The incidence of second neoplasms can be markedly decreased by deleting from potentially curative therapy certain drugs such as alkylating agents, procarbazine, and nitrosourea derivatives.

AB - The records of 1,329 patients with Hodgkin's disease admitted from 1965 to 1982 were analyzed to assess the relative frequency of second neoplasms. Within a median follow-up of 9.5 years, a total of 68 new cancers were documented. Nineteen cases of acute nonlymphocytic leukemia, 6 cases of non-Hodgkin's lymphomas, and 43 cases with different types of solid tumors were identified. The overall risk of non-Hodgkin's lymphoma was 1.3% ± 0.6% and of solid tumors was 8.3% ± 1.5% when basal cell carcinomas were included and 6.7% ± 1.4% when basal cell carcinomas were excluded. No cases of leukemia were documented in patients treated with radiation therapy only. The 12-year estimate of leukemia by treatment was as follows: chemotherapy only 1.4% ± 2.3%; radiation plus MOPP (mechlorethamine, vincristine, procarbazine, and prednisone) 10.2% ± 5.2%; radiation plus ABVD (Adriamycin, bleomycin, vinblastine, and dacarbazine) 0; and radiation plus other drug regimens 4.8% ± 1.6%. The risk of leukemia was particularly high (15.5% ± 7.4%) in patients who received salvage MOPP after radiation failure. A positive association was also noted between increasing age and risk of second malignancies, especially leukemia. The incidence of second neoplasms can be markedly decreased by deleting from potentially curative therapy certain drugs such as alkylating agents, procarbazine, and nitrosourea derivatives.

UR - http://www.scopus.com/inward/record.url?scp=0022447771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022447771&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 830

EP - 837

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 6

ER -